OJID (Oxford Journal of Infectious Diseases) 3 issue catch up (Drop 1 of 4)

Well it's been a while since I posted anything by the OJID, mostly due to other priorities project-wise and so I thought it high time I revisited them?
So in this drop we have papers on Ebola, Marburg and Covid to get through (and before the Terrain mob try screaming 'Blue Murder', how exactly do you expect to argue with these people, if your entire argument is based around, 'But viruses don't exist'?
"Know thine enemy" Sun Tzu 'The Art of War')

1) The Multiple Origins of Ebola Disease Outbreaks

2) Perspectives on Advancing Countermeasures for Filovirus Disease: Report From a Multisector Meeting

3) RNA Editing as a General Trait of Ebolaviruses

4) Ebola Virus Uses Tunneling Nanotubes as an Alternate Route of Dissemination

5) A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus

OJID (Oxford Journal of Infectious Diseases) 3 issue catch up (Drop 2 of 4)

1) Preexisting Immunity Does Not Prevent Efficacy
of Vesicular Stomatitis Virus–Based Filovirus Vaccines in Nonhuman Primates

2) Single-Dose Treatment With Vesicular Stomatitis
Virus–Based Ebola Virus Vaccine Expressing Ebola
Virus–Specific Artificial Micro-RNA Does Not Protect Mice From Lethal Disease

3) A Recombinant Vesicular Stomatitis Virus–Based Vaccine Provides Postexposure Protection Against Bundibugyo
Ebolavirus Infection

4) Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus–Infected Rhesus Macaques

5) Clinical Antiviral Efficacy of Remdesivir in Cov19: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)

OJID (Oxford Journal of Infectious Diseases) 3 issue catch up (Drop 3 of 4)

1) Stroke Following Cov19 Vaccination: Evidence Based on Different Designs of Real-World Studies

2) Herpes Zoster Reactivation After mRNA and Adenovirus-Vectored Cov19 Vaccination: Analysis of National Health Insurance Database

3) Age-Dependent Risk of Respiratory Syncytial Virus
Infection: A Systematic Review and Hazard Modeling From Serological Data

4) Interpreting the Results of Trials of BCG Vaccination for Protection Against COVID-19

5) Improving Tuberculosis Vaccine Trial Efficiency: A Tough Nut to Crack

OJID (Oxford Journal of Infectious Diseases) 3 issue catch up (Drop 4 of 4)

1) An Aspiration to Radically Shorten Phase 3 Tuberculosis Vaccine Trials

2) Time Required for Nanopore Whole-Genome Sequencing of Neisseria gonorrhoeae for Identification of Phylogenetic Relationships

3) Stability and Inactivation of Monkeypox Virus on Inanimate Surfaces

4) T-Cell Immunity Against Severe Acute Respiratory
Syndrome Coronavirus 2 Measured by an Interferon-γ Release Assay Is Strongly Associated With Patient
Outcomes in Vaccinated Persons Hospitalized With
Delta or Omicron Variants

5) Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)